Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Summary

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention…